What is it about?
DS-2969b is a new drug candidate in clinical development for treatment of Clostridium difficile infection (CDI). This paper describes ideal characteristics of DS-2969b as a drug for CDI.
Featured Image
Why is it important?
We described the potent and relatively selective activity of DS-2969b, presumably leading to low risk of recurrence because the presence of remaining bacteria allows less opportunity for regrowth of C. difficile in the intestine.
Perspectives
The promising results suggest the potential of DS-2969b as a highly improved drug for CDI. I hope some readers are interested in in-licensing of this compound and take over its further development.
Nobuhisa Masuda
Daiichi Sankyo Kabushiki Kaisha
Read the Original
This page is a summary of: In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile, Antimicrobial Agents and Chemotherapy, February 2018, ASM Journals,
DOI: 10.1128/aac.02157-17.
You can read the full text:
Contributors
The following have contributed to this page
